
Novocure Ltd
NASDAQ:NVCR

During the last 3 months Novocure Ltd insiders have not bought any shares, and sold 1.1m USD worth of shares. The stock price has dropped by 41% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nasdaq/nvcr/vs/indx/gspc">open performance analysis).
The last transaction was made on
Mar 3, 2025
by
Paravasthu Mukund
(Chief Operating Officer)
, who
sold
4.6k USD
worth of NVCR shares.
During the last 3 months Novocure Ltd insiders have not bought any shares, and sold 1.1m USD worth of shares. The stock price has dropped by 41% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nasdaq/nvcr/vs/indx/gspc">open performance analysis).
The last transaction was made on
Mar 3, 2025
by
Paravasthu Mukund
(Chief Operating Officer)
, who
sold
4.6k USD
worth of NVCR shares.
Novocure Ltd
Glance View
Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.

What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.